Positions

Selected Publications

Academic Article

Year Title Altmetric
2021 The bet inhibitor JQ1 augments the antitumor efficacy of gemcitabine in preclinical models of pancreatic cancer.  Cancers.  13. 2021
2021 Downregulation of PDGFRß Signaling Overcomes Crizotinib Resistance in a TYRO3 and ALK Mutated Neuroendocrine-Like Tumor.  Translational Oncology.  14. 2021
2021 Novel second-generation rexinoid induces growth arrest and reduces cancer cell stemness in human neuroblastoma patient-derived xenografts.  Journal of Pediatric Surgery.  56:1165-1173. 2021
2021 PIM447 inhibits oncogenesis and potentiates cisplatin effects in hepatoblastoma.  Journal of Pediatric Surgery.  56:1157-1164. 2021
2021 EZH2 inhibition decreases neuroblastoma proliferation and in vivo tumor growth.  PLoS ONE.  16. 2021
2021 9-cis-UAB30, a novel rexinoid agonist, decreases tumorigenicity and cancer cell stemness of human neuroblastoma patient-derived xenografts.  Translational Oncology.  14. 2021
2020 Developing effective combination therapy for pancreatic cancer: An overview.  Pharmacological Research.  155. 2020
2020 Patient-derived xenograft models of pancreatic cancer: Overview and comparison with other types of models.  Cancers.  12. 2020
2020 Development of gemcitabine-resistant patient-derived xenograft models of pancreatic ductal adenocarcinoma 2020
2020 The combination of BET and PARP inhibitors is synergistic in models of cholangiocarcinoma.  Cancer Letters.  468:48-58. 2020
2019 Focal Adhesion Kinase Inhibition Contributes to Tumor Cell Survival and Motility in Neuroblastoma Patient-Derived Xenografts.  Scientific Reports.  9. 2019
2019 Corruption of neuroblastoma patient derived xenografts with human T cell lymphoma.  Journal of Pediatric Surgery.  54:2117-2119. 2019
2019 The BET inhibitor JQ1 attenuates double-strand break repair and sensitizes models of pancreatic ductal adenocarcinoma to PARP inhibitors.  EBioMedicine.  44:419-430. 2019
2019 The presence of PIM3 increases hepatoblastoma tumorigenesis and tumor initiating cell phenotype and is associated with decreased patient survival.  Journal of Pediatric Surgery.  54:1206-1213. 2019
2019 Targeting PIM Kinases Affects Maintenance of CD133 Tumor Cell Population in Hepatoblastoma.  Translational Oncology.  12:200-208. 2019
2019 The effects of focal adhesion kinase and platelet-derived growth factor receptor beta inhibition in a patient-derived xenograft model of primary and metastatic Wilms tumor.  Oncotarget.  10:5534-5548. 2019
2018 FTY720 enhances the anti-tumor activity of carboplatin and tamoxifen in a patient-derived xenograft model of ovarian cancer.  Cancer Letters.  436:75-86. 2018
2018 Targeting PIM kinase as a therapeutic strategy in human hepatoblastoma.  Oncotarget.  9:22665-22679. 2018
2018 Pediatric anaplastic embryonal rhabdomyosarcoma: Targeted therapy guided by genetic analysis and a patient-derived xenograft study.  Frontiers in Oncology.  7. 2018
2018 JQ1 induces DNA damage and apoptosis, and inhibits tumor growth in a patient-derived xenograft model of cholangiocarcinoma.  Molecular Cancer Therapeutics.  17:107-118. 2018
2018 Sphingolipid metabolism and drug resistance in ovarian cancer 2018
2017 Whole exome sequencing identified sixty-five coding mutations in four neuroblastoma tumors.  Scientific Reports.  7. 2017
2016 The tumor-associated glycosyltransferase ST6Gal-I regulates stem cell transcription factors and confers a cancer stem cell phenotype.  Cancer Research.  76:3978-3988. 2016
2016 The BET bromodomain inhibitor JQ1 suppresses growth of pancreatic ductal adenocarcinoma in patient-derived xenograft models.  Oncogene.  35:833-845. 2016
2016 Dysregulated human Tyrosyl-DNA phosphodiesterase I acts as cellular toxin.  Oncotarget.  7:86660-86674. 2016
2015 ICAM-2 confers a non-metastatic phenotype in neuroblastoma cells by interaction with α-actinin.  Oncogene.  34:1553-1562. 2015
2015 The role of ICAM-2 in neuroblastoma.  Oncoscience.  2:915-916. 2015
2013 Development and Histopathological Characterization of Tumorgraft Models of Pancreatic Ductal Adenocarcinoma.  PLoS ONE.  8. 2013
2013 N-glycosylation of ICAM-2 is required for ICAM-2-mediated complete suppression of metastatic potential of SK-N-AS neuroblastoma cells.  BMC Cancer.  13. 2013
2009 Cell adhesion molecules as targets for therapy of neuroblastoma.  Cancer Biology and Therapy.  8:306-311. 2009
2008 ICAM-2 expression mediates a membrane-actin link, confers a nonmetastatic phenotype and reflects favorable tumor stage or histology in neuroblastoma.  PLoS ONE.  3. 2008
2007 Targeting methylguanine-DNA methyltransferase in the treatment of neuroblastoma.  Clinical Cancer Research.  13:5418-5425. 2007
2007 Tumor-targeted enzyme/prodrug therapy mediates long-term disease-free survival of mice bearing disseminated neuroblastoma.  Cancer Research.  67:22-25. 2007
2006 Development of a tumor-selective approach to treat metastatic cancer.  PLoS ONE.  1. 2006
2006 Development of an etoposide prodrug for dual prodrug-enzyme antitumor therapy.  Molecular Cancer Therapeutics.  5:1577-1584. 2006
2006 Translocations of 17q21∼qter in neuroblastoma cell lines infrequently include the topoisomerase IIα gene.  Cancer Genetics.  167:92-94. 2006
2005 Inhibition of acetylcholinesterase by the anticancer prodrug CPT-11.  Chemico-Biological Interactions.  157-158:247-252. 2005
2005 Inhibition of carboxylesterases by benzil (diphenylethane-1,2-dione) and heterocyclic analogues is dependent upon the aromaticity of the ring and the flexibility of the dione moiety.  Journal of Medicinal Chemistry.  48:5543-5550. 2005
2005 The crystal structure of the complex of the anticancer prodrug 7-ethyl-10-[4-(1-piperidino)-1-piperidino]-carbonyloxycamptothecin (CPT-11) with Torpedo californica acetylcholinesterase provides a molecular explanation for its cholinergic action.  Molecular Pharmacology.  67:1874-1881. 2005
2005 Identification and characterization of novel benzil (diphenylethane-1,2- dione) analogues as inhibitors of mammalian carboxylesterases.  Journal of Medicinal Chemistry.  48:2906-2915. 2005
2005 Development of prodrugs for enzyme-mediated, tumor-selective therapy 2005
2004 Characterization of inhibitors of specific carboxylesterases: Development of carboxylesterase inhibitors for translational application.  Molecular Cancer Therapeutics.  3:903-909. 2004
2004 Discovery of novel selective inhibitors of human intestinal carboxylesterase for the amelioration of irinotecan-induced diarrhea: Synthesis, quantitative structure-activity relationship analysis, and biological activity.  Molecular Pharmacology.  65:1336-1343. 2004
2003 Activation of a camptothecin prodrug by specific carboxylesterases as predicted by quantitative structure-activity relationship and molecular docking studies.  Molecular Cancer Therapeutics.  2:1171-1181. 2003
2003 Synthesis and evaluation of esters and carbamates to identify critical functional groups for esterase-specific metabolism.  Bioorganic and Medicinal Chemistry.  11:3237-3244. 2003
2003 Acetyl-L-carnitine cytoprotection against 1-methyl-4-phenylpyridinium toxicity in neuroblastoma cells..  Biochemical Pharmacology.  66:297-306. 2003
1998 New steroidal antiinflammatory agents: prednisolone derivatives with an isoxazoline fusion at the 16- and 17-carbons and an alkyl carboxylate at the 16 alpha-position. 1998
1998 The thymolytic effect of cocaine and monoaminergic drugs in the mouse..  Life Sciences.  62:905-912. 1998
1995 Steroidal anti-inflammatory antedrugs: synthesis and pharmacological evaluation of 16 alpha-alkoxycarbonyl-17-deoxyprednisolone derivatives..  Steroids.  60:445-451. 1995

Education And Training

  • Doctor of Philosophy in Pharmacology, Florida Agricultural & Mechanical University 2001

    • Full Name

  • Karina Yoon